Over expression of S100P up-regulates cancer cell proliferation: unfavorable prognosis and tumor progression in patients with endometrial cancer


 

Abstract

Endometrial cancer is the most common gynecologic malignancy. There is increasing evidence suggesting that S100P has a significant role in cancer. The objective of this study is investigate the role of S100P in promote endometrial cancer cell proliferation and S100P has received increasing attention due to accumulating evidence of its significant role during the development and progression of different cancers. Quantitative real-time RT-PCR (qPCR) analysis was used to measure changes of S100P. Transwells is used for migration and invasion assay respectively. Cell proliferation was analysed by flow cytometry. High expression of S100P are associated with invasion endometerial cancer while, knockdown of S100P protein decreased cellular proliferation and migration. In conclusion, S100P regulate endometrial cell proliferation migration and invasion and reduces chemoresistance.

Keywords: Endometrial cancer; S100P; Quantitative real-time RT-PCR

Copyright © 2019 by The American Society for BioMedicine and BM-Publisher, Inc.

Article citationReferencesFull-Text/PDFFeedback
The citation data is computed by the following citation measuring services:

Cited by (CrossRef)
Google Scholar

  1. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271-289. https://doi.org/10.3322/caac.21349
    PMid:27253694
  2. Ryan AJ, Susil B, Jobling TW, et al. Endometrial cancer. Cell Tissue Res 2005;322:53-61.
    https://doi.org/10.1007/s00441-005-1109-5
    PMid:15947972
  3. Creasman, W. T. et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95(Suppl 1), S105-143.
    https://doi.org/10.1016/S0020-7292(06)60031-3
  4. Lu, L, Shen, Y, Tseng, K‐F, Liu, W, Duan, H, Meng, W. Silencing of UCA1, a poor prognostic factor, inhibited the migration of endometrial cancer cell. Cancer Biomark. 2016; 17( 2): 171‐ 177.
    https://doi.org/10.3233/CBM-160628
    PMid:27540975
  5. Liu H, Shi J, Anandan V, Wang HL, et al. Reevaluation and identification of the best immunohistochemical panel (pVHL, maspin, S100P, IMP3) for ductal adenocarcinoma of the pancreas. Arch Pathol Lab Med. 2012;136:601-9.
    https://doi.org/10.5858/arpa.2011-0326-OA
    PMid:22646265
  6. Arumugam T, Simeone DM, Schmidt AM, Logsdon CD. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE) J Biol Chem. 2004;279:5059-5065.
    https://doi.org/10.1074/jbc.M310124200
    PMid:14617629
  7. Eritja N, Yeramian A, Chen BJ, Llobet-Navas D, Ortega E, Colas E, Abal M, Dolcet X, Reventos J, Matias-Guiu X. Endometrial carcinoma: specific targeted pathways. Adv Exp Med Biol. 2017;943:149-207.
    https://doi.org/10.1007/978-3-319-43139-0_6
    PMid:27910068
  8. Lin F, Shi J, Liu H, et al. Diagnostic utility of S100P and von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma-with implication of their roles in early tumorigenesis. Am J Surg Pathol. 2008;32:78-91.
    https://doi.org/10.1097/PAS.0b013e31815701d1
    PMid:18162774
  9. Dowen SE, Crnogorac-Jurcevic T, Gangeswaran R, et al. Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am J Pathol. 2005;166:81-92.
    https://doi.org/10.1016/S0002-9440(10)62234-1
  10. Koyuncuoglu, M. et al. Tumor budding and E-Cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer? Gynecol Oncol 125, 208-213.
    https://doi.org/10.1016/j.ygyno.2011.12.433
    PMid:22198340
  11. Zhao, Y, Yang, Y, Trovik, J, et al. A novel Wnt regulatory axis in endometrioid endometrial cancer. Can Res. 2014; 74( 18): 5103‐ 5117.
    https://doi.org/10.1158/0008-5472.CAN-14-0427
    PMid:25085246
  12. Yousif NG. Fibronectin promotes migration and invasion of ovarian cancer cells through up‐regulation of FAK-PI 3 K/A kt pathway. Cell biology international 2014;38:85-91.
    https://doi.org/10.1002/cbin.10184
    PMid:24115647
  13. Kumar D, Gokhale P, Broustas C, Chakravarty D, Ahmad I, Kasid U. Expression of SCC-S2, an antiapoptotic molecule, correlates with enhanced proliferation and tumorigenicity of MDA-MB 435 cells. Oncogene. 2004;23(2):612-616.
    https://doi.org/10.1038/sj.onc.1207123
    PMid:14724590
  14. Rauh-Hain, J. A. & Del Carmen, M. G. Treatment for advanced and recurrent endometrial carcinoma: combined modalities. Oncologist 15, 852-861.
    https://doi.org/10.1634/theoncologist.2010-0091
    PMid:20660059 PMCid:PMC3228028
  15. Yousif NG, Al-Amran F, Hadi N, Lee J, Adrienne J. Expression of IL-32 modulates NF-κB and p38 MAP kinase pathways in human esophageal cancer. Cytokine 2013;61:223-227.
    https://doi.org/10.1016/j.cyto.2012.09.022
    PMid:23107826
  16. Filipek A, Jastrzebska B, Nowotny M, Kuznicki J. CacyBP/SIP, a calcyclin and Siah-1-interacting protein, binds EF-hand proteins of the S100 family. J Biol Chem. 2002;277:28848-28852.
    https://doi.org/10.1074/jbc.M203602200
    PMid:12042313
  17. Singh, M. et al. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol 21, 912-923. https://doi.org/10.1038/modpathol.2008.82
    PMid:18487993
  18. Gotzmann J, Mikula M, Eger A, et al. Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res 2004;566:9-20.
    https://doi.org/10.1016/S1383-5742(03)00033-4
  19. Wang DG, Yousif NG, Sadiq AM, et al. Critical role of SEMA5A expression in invasion and metastasis of ovarian cancer cell. American Journal of BioMedicine 2014;2(3):292-305.
    https://doi.org/10.18081/2333-5106/014-03/292-305
  20. Cirisano FD, Jr, Robboy SJ, Dodge RK, et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol. 1999;74:385-94.
    https://doi.org/10.1006/gyno.1999.5505
    PMid:10479498
  21. Price FV, Amin RM, Sumkin J. Complete clinical responses to neoadjuvant chemotherapy for uterine serous carcinoma. Gynecol Oncol. 1999;73:140-4. doi: 10.1006/gyno.1998.5303.
    https://doi.org/10.1006/gyno.1998.5303
    PMid:10094895
  22. de Boer SM, Powell ME, Mileshkin L, et al. on behalf of the portec Study Group. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (portec-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:295-309.
    https://doi.org/10.1016/S1470-2045(18)30079-2
  23. Usach I, Blansit K, Chen LM, et al. Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas. Am J Obstet Gynecol. 2015;212:188.e1-6.
    https://doi.org/10.1016/j.ajog.2014.08.016
    PMid:25149685
  24. Yousif NG, Sadiq AM, Yousif MG, Al-Mudhafar RH, Al-Baghdadi JJ, Hadi NR. Notch1 ligand signaling pathway activated in cervical cancer: poor prognosis with high-level JAG1/Notch1. Archives of Gynecology and Obstetrics 2015;292:899-904. https://doi.org/10.1007/s00404-015-3694-1
    PMid:25842263
  25. Batista TP, Cavalcanti CL, Tejo AA, Bezerra AL. Accuracy of preoperative endometrial sampling diagnosis for predicting the final pathology grading in uterine endometrioid carcinoma. Eur J Surg Oncol. 2016;42:1367-71.
    https://doi.org/10.1016/j.ejso.2016.03.009
    PMid:27052799

READ THE FULL ARTICLE

1. Access this article through OpenAthens

2. Access this article through your login credentials/Subscription

Get Access

3. Purchase this article at rate $55.00 and received Full-Text/PDF
You will have online immediate access to article following the completion of this purchase and you may download and print a copy of each article for your personal use. Use the coding below to purchase your article as PDF by credit card, debit card, will be asked to supply your billing card information. Before continue with your purchase please read carefully the BM-Publisher terms and conditions of purchase.

Purchase Article

For any technique error please contact us and will be response to sending purchase article by email.

Who Can Become a Reviewer?
Any expert in the article's research field can become a reviewer with American Journal of Biomedicine. Editors might ask you to look at a specific aspect of an article,...

Find out more

Thank you for visiting American Journal of BioMedicine. * = Required fields

Research Article
DOI: http://dx.doi.org/10.18081/2333-5106/019-02/79-103
American Journal of BioMedicine Volume 7, Issue 2, pages 79-103
Received October 17, 2018; accepted January 17, 2019; published February 19, 2019

How to cite this article
Jonathan A. Serody, Kerry R. Russell, Rui Chen, Mark B. Ferrara. Over expression of IL-32β- exaggerated myocardial injury after ischemia and reperfusion in mice model. American Journal of BioMedicine 2019;7(2):57-69.

Case report outline
1. Abstract
2. Keywords
3. Introduction
4. Methods
5. Results
6. Discussion
7. References

Explore PlumX Metrics

American Journal of Biomedicine © 2018 BM-Publisher
%d bloggers like this: